Ward, MD - Owner Shamblaw, MD

80 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------ 073 H Slide Session New Antiretroviral Therapy: Bench to Bedside Monday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 104 UAN: 0391-9999-12-077-L04-P Moderators: Douglas J. Ward, MD - Physician Dupont Circle Physicians Group, Washington, DC. Joseph Eron, Jr., MD - Professor of Medicine Univ. of North Carolina, Chapel Hill, NC. Objectives: Upon the completion of this Slide Session, the participant should be able to: Describe mechanisms of action of new antiretroviral therapy; Assess the antiretroviral response to fixed dose combination therapy; and Discuss the advantages and disadvantages on switching antiretroviral therapy. Presentations: 8:30 a.m. H-550 Antiviral Characteristics of SGSK1265744, an HIV Integrase Inhibitor INI Dosed by Oral or Long-Acting Parenteral Injec- tion

T. Yoshinaga, PhD - Section Head

1 , M. Kobayashi, MS - Section Head 1 , T. Seki, PhD - Team Leader 1 , T. Kawasuji, MS - Section Head 1 , T. Taishi, MS - Team Leader 1 , A. Sato, PhD - Department Head 1 , T. Fujiwara, PhD - Project Leader 1 , B. Johns, PhD - Medicinal Chemist 2 , R. Hazen, PhD - Virology 2 , R. Ferris, PhD - Virology 2 , M. Underwood, PhD - Virology 2 ; 1 Shionogi, Toyonaka, Japan, 2 GlaxoSmithKline, Research Triangle Park, NC. 8:45 a.m. H-551 Antiviral Activity and In Vitro Mutation Development Path- ways of MK-1439: A Novel Non-Nucleoside Reverse Transcrip- tase Inhibitor

M. Lai, PhD- Program Lead

1 , M. Feng, MS - Research Assistant 1 , M. Lu, MS - Research Assistant 1 , E. Asante-Appiah, PhD - Program Lead 2 , P. Tawa, MS - Research Assistant 2 , M. Witmer, MS - Research Assistant 1 , D. DiStefano, MS - Program Lead 1 , E. Cauchon, MS - Research Assistant 3 , L. Campeau, PhD - Program Lead 4 , Y. Yan, PhD - Program Lead 1 , M. Miller, PhD - Program Lead 1 , D. Hazuda, PhD - Vice President 1 ; 1 Merck Co. Inc., West Point, PA, 2 Merck Co. Inc., Kenilworth, NJ, 3 Merck Co. Inc., Pointe Claire, Canada, 4 Merck Co. Inc., Rahway, NJ. 9:00 a.m. H-552 Virological Profiling of GS-7340, a Next-Generation Tenofo- vir Prodrug with Superior Potency Over TDF

C. Callebaut, PhD - Sr Scientist, N. Margot, MS - Associate Scientist, G.

Stepan, BS - Associate Scientist, Y. Tian, PhD - Research Scientist, M. Miller, PhD - Sr Director; Gilead Sci., Foster City, CA. 9:15 a.m. H-553 Preferential Expansion of Transitional T TM and Central Memory T CM CD4 T-Cells following Adoptive Transfer of ZFN CCR5 Modified Autologous CD4 T-Cells SB-728-T

J. Zeidan, PhD - Fellow

1 , R. Bordi, PhD - Fellow 1 , S. Deeks, MD - Profes- sor 2 , R. Mitsuyasu, MD - Professor 3 , J. Lalezari, MD - Director 4 , G. Lee, PhD - Assoc Director 5 , S. Wang, MD - Director 5 , W. W. Tang, MD - VP 5 , G. Nichol, MD - EVP 5 , M. Giedlin, PhD - VP 5 , R. Sekaly, PhD - Director 1 , D. Ando, MD - CMO 5 ; 1 VGTI, Port St Lucie, FL, 2 UCSF, San Francisco, CA, 3 UCLA, Los Angeles, CA, 4 Quest Clin Res, San Francisco, CA, 5 San- gamo Biosciences Inc, Richmond, CA. 9:30 a.m. H-554 Albuvirtide, the First Long-Acting HIV Fusion Inhibitor, Suppressed Viral Replicaiton in HIV-Infected Adults H. Wu, MD - Division Chief 1 , C. Yao, PhD - Medical Manager 2 , R. J. Lu, PhD - Vice President 2 , T. Zhang, MD - Professor 1 , M. X. Wang, PhD - Professor 1 , H. X. Zhao, MD - Professor 3 , H. Y. Peng, MS - Research Assistant 4 , Y. Xie, BS - Research Assistant 2 , W. J. Min, MS - Research Assistant 2 , H. Jiang, PhD - Professor 2 , C. J. Wang, PhD - Professor 2 , D. Xie, PhD - Chief Scientific Officer 2 , R. H. Jin, MD - Professor 1 ; 1 Beijing You’an Hosp., Capital Med. Univ., Beijing, China, 2 Chongqing Frontier Biotechnologies Co. Ltd., Chongqing, China, 3 Beijing Ditan Hosp., Capital Med. Univ., Beijing, China, 4 Beijing Kao Ke Rui Co., Beijing, China. 9:45 a.m. H-555 Efficacy and Safety of ElvitegravirCobicistatEmtricitabine Tenofovir DF from an Integrated Analysis of Phase 2 and 3 Clini- cal Trials

D. Ward, MD - Owner

1 , G. Crofoot, MD - Owner 2 , D. Shamblaw, MD - Owner 3 , N. Bellos, MD - Owner 4 , C. Kinder, MD - Owner 5 , M. Rhee, MD - As. Dir. 6 ; 1 Dupont Cir Physicians Gr, Wash, DC, 2 Gordon E. Crofoot, MD, Houston, TX, 3 La Playa Med and Clin Res, San Diego, CA, 4 South- west Infectious Disease Clin Res., Dallas, TX, 5 Kinder Med Gr., Miami, FL, 6 Gilead, Foster City, CA. 10:00 a.m. H-556 Switching to the Single-Tablet Regimen STR Emtric- itabineRilpivirineTenofovir DF FTCRPVTDF from a Rito- navir-Boosted Protease Inhibitor PI+RTV and Two Nucleoside Reverse Transcriptase Inhibitors Maintains HIV Suppression and is Well Tolerated in HIV-1 Subjects at Week 24 Regardless of Age: SPIRIT Study

D. Shamblaw, MD

1 , F. Palella, MD 2 , P. Ruane, MD 3 , P. Tebas 4 , B. Gazzard 5 , M. Fisher 6 , J. van Lunzen 7 , J. Flamm 8 , R. Ebrahimi 9 , K. White 9 , H. Graham 9 , B. Guyer, PharmD 9 , T. Fralich 9 , S. K. Chuck 9 ; 1 La Playa Med. Group, San Diego, CA, 2 Northwestern Univ. Feinberg Sch. of Med., Chicago, IL, 3 Peter J. Ruane, MD, Inc., Los Angeles, CA, 4 Univ. of Penn., Philadelphia, PA, 5 Chelsea and Westminster Hosp., London, United Kingdom, 6 Brighton and Sussex Univ. Hosp., Brighton, United Kingdom, 7 Univ. Med. Ctr Hamburg- Eppendorf, Hamburg, Germany, 8 Kaiser Permanente, Sacramento, CA, 9 Gilead Sci., Foster City, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. 81 MONDAY SCIENTIFIC SESSIONS Final Program ------------------------------------------------------------------------ 074 K Slide Session Multidrug-Resistant Organisms and Catheter-Related Infections Monday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 254 UAN: 0391-9999-12-078-L04-P Moderator: Sylvia Munoz-Price, MD - Associate Professor of Medicine Jackson Mem. Hosp., Univ. of Miami, Miami, FL. Objectives: Upon the completion of this Slide Session, the participant should be able to: Understand the epidemiology of MDROs in longterm care facilities; List factors associated with survival of Acinetobacter baumannii in desiccat- ing conditions; and Describe successful approaches to treating meningitis caused by multidrug resistant Acinetobacter. Presentations: 8:30 a.m. K-557 Prevention of Carbapenem-Resistant Enterobacteriaceae CRE Spread in Long-Term Acute Care Facilities LTACF Via a National Intervention

D. Ben-David, MD - Physician, S. Masarwa, MD - Nurse, A. Adler, MD